# Every patient on an accelerated-approval drug enrolled in a registry until confirmation

Source: https://onco.cc/ideas/idea-data-accelerated-approval-registry-condition/  
OnCo record `idea-data-accelerated-approval-registry-condition` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Accelerated approvals rest on surrogate endpoints, and confirmatory trials take years and are sometimes never completed. Making registry enrolment with automatic outcome capture a condition of prescribing under accelerated approval would give regulators a real-world signal on benefit and toxicity within about two years, while the confirmatory trial runs.

## Summary

Accelerated approvals rest on surrogate endpoints; confirmatory trials take a median of several years and some are never completed. The proposal makes registry enrolment with automatic outcome capture (via mCODE and registry linkage) a condition of prescribing under accelerated approval, giving regulators an interim real-world signal on survival and toxicity while the confirmatory trial runs. The FDA's 2023 authority to require confirmatory trials be underway at approval is the policy hook; the registry is the complementary data hook.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Mandatory registries will detect lack of overall survival benefit for accelerated-approval indications that later fail confirmation at least 18 months earlier than the confirmatory trial does.
- Rationale: Several accelerated-approval oncology indications were withdrawn only after years of use; real-world survival on those drugs was knowable much earlier had the data been collected.
- Proposed test: Retrospectively emulate the registry for five withdrawn indications using existing real-world data and estimate when a survival signal would have been detectable; prospectively apply to the next ten accelerated approvals.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019): https://doi.org/10.1001/jamainternmed.2019.0462

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- terms: [Accelerated approval](https://onco.cc/terms/accelerated-approval/), [Overall survival (OS)](https://onco.cc/terms/os/), [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval](https://onco.cc/key-papers/paper-gyawali-jama-intern-med/)

---
JSON: https://onco.cc/api/v1/entities/idea-data-accelerated-approval-registry-condition.json